Last reviewed · How we verify
Renvela
At a glance
| Generic name | Renvela |
|---|---|
| Also known as | Sevelamer carbonate, Sevelamercarbonate |
| Sponsor | Ardelyx |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
Approved indications
- Renal Osteodystrophy with Hyperphosphatemia
- Renal dialysis
Common side effects
- Vomiting
- Nausea
- Diarrhea
- Dyspepsia
- Abdominal pain
- Flatulence
- Constipation
Serious adverse events
- Peritonitis
- Intestinal perforation
- Intestinal obstruction
- Ileus
- Fecal impaction
- Bleeding gastrointestinal ulcers
- Colitis
- Ulceration
- Necrosis
- Hypersensitivity
Key clinical trials
- AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia (PHASE3)
- FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease (PHASE3)
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
- Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia (PHASE2)
- Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders (PHASE4)
- Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis (PHASE3)
- A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients (PHASE2)
- Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |